Update: RGRX Up 30.77% Since Our Alert 4 Market Days Ago

RegeneRx Biopharmaceuticals Inc. (OTCQB: RGRX)


 RegeneRx Biopharmaceuticals Inc. (OTCQB: RGRX) is Up 30.77 since our alert at 11:00 AM on April 23rd. 

Since the alert was issued, volume has been at or near 500K each day. 

See that alert HERE

Proof The Alert Really Went Out: 

About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, cardiac and dermal indications, three active strategic licensing agreements in China, Pan Asia (Korea, Japan, and Australia, among others) and the U.S., and has an extensive worldwide patent portfolio covering its products.  RGN-259, the Company’s TB4-based ophthalmic drug candidate, has been designated an orphan drug for the treatment of neurotrophic keratopathy (NK), which is a primary focus of RegeneRx’s clinical development efforts in the U.S through its joint venture, ReGenTree.  RegeneRx was recently allowed by the FDA to move into phase 3 clinical trials with RGN-259 for the treatment of patients with NK.  RGN-352, the Company’s TB4-based injectable drug candidate, is a phase 2-ready drug candidate designed to be administered systemically to prevent and restore tissue damage associated with acute events such as heart attacks, strokes, and other similar injuries. For additional information about RegeneRx please visit www.regenerx.com.

Share this post